Skip to main content Accessibility help
×
Home
Hostname: page-component-55b6f6c457-kv5sj Total loading time: 0.12 Render date: 2021-09-28T02:37:09.454Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Article contents

958 – Efficacy Of Lisdexamfetamine Dimesylate In Children And Adolescents With Attention-deficit/hyperactivity Disorder: Effect Of Age, Sex And Baseline Disease Severity

Published online by Cambridge University Press:  15 April 2020

M. Lecendreux
Affiliation:
Pediatric Sleep Center, CHU Robert Debré, Paris, France
T. Banaschewski
Affiliation:
Child and Adolescent Psychiatry and Psychotherapy, Central Institute of Mental Health, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany
C. Soutullo
Affiliation:
Child and Adolescent Psychiatry Unit, Department of Psychiatry and Medical Psychology, University Clinic of Navarra, Pamplona, Spain
M. Johnson
Affiliation:
Child Neuropsychiatry Unit, Queen Silvia Children's Hospital, Gothenburg, Sweden
A. Zuddas
Affiliation:
Department of Biomedical Sciences, Section of Neuroscience and Clinical Pharmacology, University of Cagliari, Cagliari, Italy
C. Anderson
Affiliation:
Shire Development LLC, Wayne, PA, USA
R. Civil
Affiliation:
Shire Development LLC, Wayne, PA, USA
N. Higgins
Affiliation:
Shire Development LLC, Wayne, PA, USA
R. Bloomfield
Affiliation:
Shire Pharmaceutical Development Ltd, Basingstoke
L. Squires
Affiliation:
Shire Development LLC, Wayne, PA, USA
D. Coghill
Affiliation:
Division of Neuroscience, Ninewells Hospital, Dundee, UK
Get access

Abstract

Introduction

In a European, phase 3 study (SPD489-325), lisdexamfetamine dimesylate (LDX) was more effective than placebo in improving symptoms and global functioning in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).

Objectives and aims

To evaluate the impact of age, sex and baseline disease severity on efficacy outcomes in SPD489- 325.

Methods

This 7-week, double-blind, parallel-group, dose-optimized study enrolled patients aged 6-17 years with ADHD. Patients were randomized (1:1:1) to once-daily LDX (30, 50 or 70mg/day), osmotic-release oral system methylphenidate (OROS-MPH; 18, 36 or 54mg/day) or placebo. Efficacy outcomes were analysed in patients dichotomized by age (6-12 years [n=229] or 13-17 years [n=88]), sex (male [n=255] or female [n=62]) and baseline ADHD Rating Scale version IV (ADHD-RSIV) total score (28-41 [n=161] or 42-54 [n=152]). Endpoint was the last on-treatment visit with a valid assessment.

Results

At endpoint, differences (active-placebo) in least-squares mean changes from baseline in ADHD-RS-IV total scores were statistically significant in all age, sex and ADHD-RS-IV total score subgroups for LDX (p< 0.001; effect sizes, 1.68-2.26) and OROS-MPH (p< 0.01; effect sizes, 0.88-1.46). Proportions of patients with a Clinical Global Impressions-Improvement rating of 1 (very much improved) or 2 (much improved) were statistically significantly greater than placebo at endpoint in all subgroups receiving LDX (p< 0.01) and in all subgroups except females receiving OROS-MPH (p< 0.05).

Conclusions

LDX showed greater efficacy than placebo in children and adolescents with ADHD, regardless of their age, sex or baseline disease severity.

Supported by: Funding from Shire Development LLC.

Type
Research Article
Copyright
Copyright © European Psychiatric Association 2013

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)
Submit a response

Comments

No Comments have been published for this article.
1
Cited by

Send article to Kindle

To send this article to your Kindle, first ensure no-reply@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about sending to your Kindle. Find out more about sending to your Kindle.

Note you can select to send to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be sent to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

958 – Efficacy Of Lisdexamfetamine Dimesylate In Children And Adolescents With Attention-deficit/hyperactivity Disorder: Effect Of Age, Sex And Baseline Disease Severity
Available formats
×

Send article to Dropbox

To send this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Dropbox.

958 – Efficacy Of Lisdexamfetamine Dimesylate In Children And Adolescents With Attention-deficit/hyperactivity Disorder: Effect Of Age, Sex And Baseline Disease Severity
Available formats
×

Send article to Google Drive

To send this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you use this feature, you will be asked to authorise Cambridge Core to connect with your <service> account. Find out more about sending content to Google Drive.

958 – Efficacy Of Lisdexamfetamine Dimesylate In Children And Adolescents With Attention-deficit/hyperactivity Disorder: Effect Of Age, Sex And Baseline Disease Severity
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *